Aceon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aceon

Property Description
Active ingredient Perindopril (as perindopril erbumine)
Form Oral tablets
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
General purpose To regulate blood pressure and vascular resistance
Origin Synthetic compound

What Type of Medicine is Aceon (Perindopril)?

Aceon is a prescription-only medicine whose active ingredient is the chemical substance perindopril, typically supplied as the salt perindopril erbumine. It is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, which is a high-level pharmacological class of antihypertensive agents. This medicine belongs to the group of drugs used to counteract high blood pressure. Perindopril is a synthetic compound derived from chemical synthesis, not natural sources, and is characterized by its stable structure. The medication is presented as a single-ingredient product and is formulated exclusively as oral tablets for systemic delivery, its designated route of administration.


Aceon Composition and its Role as a Prodrug

The oral tablets contain the active substance perindopril erbumine alongside pharmaceutical excipients required to form the medicine. A key aspect of its composition, which differentiates it from its active metabolite, is that perindopril itself is an inert prodrug; it is not pharmacologically active in its administered state. Following its ingestion, the body must hydrolyze the substance, primarily in the liver, to generate the active metabolite, perindoprilat, which is the molecule that actually performs the function of ACE inhibition. This conversion process shows that the body must transform the substance before it can start to work.


General Purpose of an ACE Inhibitor like Aceon

The primary purpose of Aceon, as an ACE Inhibitor, is to influence the body’s renin-angiotensin-aldosterone system (RAAS), a crucial regulatory pathway for blood pressure. The drug’s effect is to help relax blood vessels and manage the total fluid circulating in the cardiovascular system. This action decreases the force exerted on the blood vessel walls and reduces the overall resistance against which the heart must pump, thus promoting improved circulation and easing the workload on the heart muscle. A typical neutral use scenario for this class involves supporting patients who need sustained, daily management of vascular resistance.

Regulatory References

  1. FDA Drug Record for Perindopril Erbumine

What side effects are possible with Aceon?

Aceon (perindopril) is an Angiotensin-Converting Enzyme (ACE) inhibitor whose safety profile and adverse reactions are officially documented by government regulatory agencies, classified by frequency and body system affected.

Frequency-Classified Adverse Reactions

The most common event, classified as Very Common (occurring in ge 10% of patients), is a Cough, typically persistent and nonproductive. Reactions classified as Common (1% to 10%) often include Headache, Dizziness, Asthenia (weakness), Hypotension (low blood pressure), and Gastrointestinal Disturbances such as nausea, vomiting, or diarrhea. Less frequent reactions, classified as Uncommon or Rare, involve other systems, including a risk of elevated potassium levels (Hyperkalemia).

Serious Regulatory Warnings

The official labeling highlights several serious adverse reactions. The most significant is Angioedema, which is rapid swelling of the face, extremities, lips, tongue, or larynx that can occur at any time during therapy. Another major concern is Fetal Toxicity; the use of perindopril during the second and third trimesters of pregnancy is strictly contraindicated due to the risk of injury or death to the developing fetus. Symptomatic Hypotension is also noted, being most likely to occur following the initial dose or a dose increase, especially in susceptible patients.

Population-Specific Safety Constraints

Safety concerns are explicitly documented for certain groups. Black patients have a reported higher incidence of angioedema. Dosage considerations are necessary for older adults and those with renal impairment, where the drug's elimination is decreased. Furthermore, the medicine is contraindicated in patients with a history of angioedema related to a previous ACE inhibitor or those using a Neprilysin Inhibitor.

Overdose and Emergency Response

Overdose and when to seek help

This information details the officially documented manifestations and required emergency actions for an overdose of Aceon (perindopril erbumine), as defined by government regulatory authorities.


Documented Overdose Manifestations

Primary Manifestation Severe Secondary Outcomes
The most likely clinical sign of overdose is excessive hypotension (severely low blood pressure). This can manifest as dizziness, lightheadedness, or fainting. Consequences of severe hypotension may include acute renal failure, oliguria, and azotemia. In susceptible patients, an excessive fall in blood pressure may lead to a myocardial infarction or a cerebrovascular accident.

Emergency Actions and Management

Regulatory documents mandate that for any suspected overdose or experience of excessive hypotension, immediate medical attention must be sought. Contact emergency services is required.

Immediate Action Supportive Management
Place the patient immediately in a supine position to manage severe hypotension. Management is symptomatic and supportive. This includes administering an intravenous infusion of physiological saline for volume expansion. Officially, no specific antidote is known; however, the active metabolite, perindoprilat, is removable by dialysis.

Official labeling notes that patients with pre-existing conditions, such as renal impairment or volume depletion, face a heightened risk of severe outcomes from excessive hypotension, requiring very close medical monitoring.

Therapeutic Uses of Aceon

Main Uses of Aceon

Aceon, known by its generic name perindopril erbumine, is a medication belonging to the class of drugs called angiotensin-converting enzyme (ACE) inhibitors. It is primarily utilized in clinical practice for the management of cardiovascular health through two main indications.

Treatment of Essential Hypertension

The primary use of Aceon is for the treatment of essential hypertension, commonly known as high blood pressure. In patients with hypertension, the medication works by inhibiting the enzyme responsible for converting angiotensin I to angiotensin II. Since angiotensin II is a potent substance that causes blood vessels to tighten and narrow, reducing its production allows the blood vessels to relax and widen. This process helps to lower blood pressure levels toward a more typical range.

Reduction of Risk in Stable Coronary Artery Disease

Aceon is also indicated for use in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction (heart attack). In this context, it is often used to improve the prognosis of individuals who have a documented history of heart disease but are currently in a stable clinical state. By modulating the renin-angiotensin-aldosterone system, the medication provides a protective effect on the vascular system and heart muscle.

Benefits and Mechanism

The clinical benefits of Aceon stem from its ability to systemic vascular resistance without significantly increasing the heart rate. This provides several physiological advantages:

  • Improved Blood Flow: By promoting vasodilation, the medication facilitates easier blood flow throughout the body, reducing the workload placed on the heart.
  • Organ Protection: Long-term management of blood pressure with ACE inhibitors is associated with the protection of vital organs, such as the kidneys and the heart, from the damage caused by chronic hypertension.
  • Secondary Prevention: In patients with established heart disease, the medication serves as a preventative measure to lower the likelihood of future major cardiac events.

Regulatory References

  1. NIH DailyMed Overview of Perindopril

Eligibility and Restrictions for Use

Who Can and Cannot Use Aceon? (Perindopril)

This section outlines the official population eligibility and non-eligibility rules for Aceon, as documented in governmental regulatory labeling.

Aceon is established for use in adults for its approved indications. However, use is not established and not recommended in the pediatric population (children and adolescents under 18 years).


Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated for several populations, including:

  • Patients with a history of angioedema (swelling) related to any previous ACE inhibitor use, or those with hereditary angioedema.
  • Patients in the Second and Third Trimesters of Pregnancy. Aceon must be stopped immediately if pregnancy is detected.
  • Patients taking a neprilysin inhibitor (e.g., sacubitril) or the combination product sacubitril/valsartan.
  • Patients with diabetes who are concurrently taking the direct renin inhibitor aliskiren.
  • Patients with severe renal impairment (creatinine clearance less than 30 mL/min).

Restricted and Conditional Use

Use is not recommended in the First Trimester of Pregnancy and in breastfeeding patients. Caution is advised for older adults (over 65 years) and patients with hepatic impairment. Use is conditional and requires close monitoring in patients who are volume-depleted (low salt/fluid status) or who have renovascular hypertension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aceon (perindopril) has officially documented interaction patterns that are primarily categorized by their effect on the Renin-Angiotensin-Aldosterone System (RAAS) and potassium homeostasis. These classifications, established by regulatory bodies, govern the required constraints and prohibitions for co-administration.

Official Interaction Statements

  • Sacubitril/Valsartan is a formally contraindicated combination, requiring a mandatory washout period before use, due to the documented risk of angioedema.
  • The use of Aliskiren is strictly contraindicated in patients with diabetes mellitus or renal impairment, as this significantly increases the risks associated with dual RAAS blockade.
  • Concomitant use with Potassium-Sparing Diuretics (e.g., Spironolactone) or Potassium Supplements is generally not recommended due to the officially documented risk of hyperkalemia.
  • Co-administration with Lithium can result in increased serum concentrations of lithium, leading to a general recommendation against combined use.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a diminished antihypertensive effect and increase the risk of deterioration of renal function.
  • Extracorporeal treatments involving high-flux membranes are contraindicated due to the risk of severe anaphylactoid reactions.
  • Administration is officially recommended before a meal once daily.

The official interaction profile strictly defines these combinations based on documented risks of dual RAAS blockade, severe adverse reactions, and altered systemic clearance.

Mechanism of Action

Aceon (perindopril erbumine) is an ethyl ester prodrug that undergoes in vivo hydrolysis to form its active metabolite, perindoprilat. This metabolite functions as a non-sulfhydryl, competitive inhibitor of the somatic form of Angiotensin-Converting Enzyme (ACE), which is also known as Kininase II.

The binding of perindoprilat to ACE blocks the conversion of the inactive decapeptide Angiotensin I to the potent vasoconstrictor octapeptide Angiotensin II within the Renin-Angiotensin-Aldosterone System (RAAS). This inhibition leads to a systemic decrease in circulating and local tissue levels of Angiotensin II.

The intracellular consequence is reduced aldosterone secretion from the adrenal cortex, which subsequently decreases sodium and water reabsorption in the distal convoluted tubules. Furthermore, perindoprilat's inhibition of Kininase II reduces the degradation of the vasodilator peptide bradykinin, potentially resulting in elevated bradykinin levels.

Downstream, these molecular events lead to systemic vasodilation, a decrease in plasma volume, and reduced vascular resistance. This overall modulation of the RAAS and kinin pathways results in a net reduction in systemic blood pressure.

Dosage and Administration Information

Administration of Aceon (Perindopril Erbumine) Tablets

Aceon is administered according to specific dosing regimens tailored to the condition being treated and the individual patient's clinical profile.

Administration and Frequency

Aceon is taken orally (by mouth). The medication is generally administered once a day as a single daily dose. For some regimens, the daily dose may be given in two divided doses. Dosing is adjusted based on the specific condition being managed.

Condition Initial Dose Maintenance Dose Maximum Dose
Hypertension 4 mg once daily 4 mg to 8 mg once daily or divided 16 mg per day
Stable Coronary Artery Disease (CAD) 4 mg once daily for 2 weeks 8 mg once daily 8 mg per day

Special Dosing Instructions

Specific dose adjustments are utilized for certain patient groups:

  • Elderly Patients (>70 years): For Stable CAD, the initial dose is 2 mg once daily for the first week, then 4 mg once daily for the second week, before proceeding to the 8 mg maintenance dose if tolerated. For hypertension, the initial dose is 4 mg daily (in one or two divided doses), with limited experience for doses above 8 mg.
  • Renal Impairment: For patients with a creatinine clearance (CrCl) greater than or equal to 30 mL/min, the initial dosage is 2 mg/day and the maximum daily dosage should not exceed 8 mg/day. Aceon is not recommended for patients with CrCl less than 30 mL/min.
  • Use with Diuretics: To reduce the likelihood of symptomatic hypotension, the diuretic may be discontinued 2 to 3 days before initiating Aceon. If the diuretic cannot be stopped, the initial dose of Aceon is typically lower, ranging from 2 mg to 4 mg daily in one or two divided doses, administered under medical supervision.

Missed Dose

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped and the regular dosing schedule is resumed. A double dose should not be taken to compensate for the missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aceon

Evidence for Essential Hypertension

Clinical evaluation of Aceon (perindopril) for managing Essential Hypertension is primarily based on Randomized Controlled Trials (RCTs) conducted in adults. These studies compare perindopril against inactive substances or other blood pressure medications. Researchers track outcomes related to physiological strain by measuring changes in blood pressure over time and examine whether use was associated with the achievement of specific blood pressure goals. Long-term observational settings also collect data on major cardiovascular events. Some long-term outcomes data are consolidated into meta-analyses that combine results from multiple drugs in the same class, meaning the specific long-term impact of perindopril alone is evaluated as part of the evidence for the drug class.

Evidence for Cardiovascular Conditions

Perindopril was evaluated in large-scale, long-term clinical trials for Stable Coronary Artery Disease and Mild to Moderate Congestive Heart Failure. For stable coronary artery disease, trials monitored serious outcomes describing episodic changes, such as heart attack and hospitalization, over several years. For heart failure, studies focused on outcomes reflecting daily functioning, including hospitalization frequency and changes in functional status. Research describes a pattern of reduced recorded rates of hospitalization and gathered data to evaluate differences in long-term mortality patterns between the observed populations.

Evidence Limitations and Uncertainty

Comparative evidence is lacking for perindopril against some newer therapies used in managing heart failure. The evidence base for pediatric populations remains insufficient for most indications, meaning the results apply only to the adults studied in the main trials. Additionally, while long-term studies exist, the long-term effects are not fully established beyond the typical follow-up durations of key trials, and research is ongoing to fill these gaps. Findings describe group patterns, not personal outcomes; research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Aceon (FAQ)

Q: How quickly does Aceon begin to lower blood pressure after starting treatment?

Official clinical pharmacology information indicates that the active form of Aceon begins to reach its peak concentration in the blood within a few hours of taking a dose. The maximum blood pressure lowering effect is typically observed approximately 6 to 10 hours after dosing. The blood pressure-lowering pattern generally increases over several weeks.

Q: What is the expected timeline for Aceon to reach its full effect on blood pressure?

Official studies show that the full blood pressure reduction patterns studied are typically observed after several weeks of continuous treatment. While the effect is noticeable after the first dose, the overall optimization of the drug’s impact may take a few weeks. The blood pressure-lowering effect is expected to persist for 24 hours after a once-daily dose.

Q: Is Aceon considered a common or standard medication for high blood pressure?

Yes, Aceon (perindopril) is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This is a well-established and commonly prescribed class of drugs specifically used for the management of high blood pressure and certain other cardiovascular conditions.

Q: Is it normal to feel dizzy or light-headed when first starting Aceon?

Dizziness is a commonly reported side effect when taking Aceon. Regulatory guidance notes that symptomatic low blood pressure (hypotension) is most likely to occur after the very first dose or when the dose is increased. Official guidance often includes the suggestion to rise slowly when changing position as a general precaution.

Q: Does the dizziness from Aceon usually go away over time, or is it permanent?

Patient information indicates that symptoms like dizziness are more common during the initial adjustment period, suggesting they may lessen as treatment continues. This is related to the initial effects on blood pressure and may stabilize after the body adjusts to the medication.

Q: Can Aceon cause a change in vision, such as blurry vision or eye pain?

Official product information lists visual disturbances, such as blurry vision, as a reported side effect of the medication. This is generally classified as a less frequent event, occurring in a small percentage of patients.

Q: Is there information available about the use of Aceon during breastfeeding?

Official guidance indicates that Aceon is generally not recommended for use by patients who are breastfeeding. Information from medical databases suggests that only low levels of the drug and its active form pass into breast milk.

Q: Is Aceon an appropriate medication for use in children or adolescents?

Official regulatory documents state that the safety and effectiveness of Aceon have not been established in the pediatric population (children and adolescents). For this reason, official prescribing information does not recommend its use in these age groups.

Q: Is it common for Aceon to cause a rash, and is a rash a sign of a serious reaction?

Rash and pruritus (itching) are listed in official documents as common side effects. While the most serious documented swelling (angioedema) is rare, severe skin rashes like Stevens-Johnson Syndrome are also noted as very rare but serious adverse reactions.

Q: Could Aceon cause a metallic taste or a change in the ability to taste food?

Yes, regulatory data indicates that taste disturbances, known technically as dysgeusia, are a commonly reported side effect of Aceon. Additionally, dry mouth has been reported as an uncommon side effect in official reports.

Q: Is there an increased risk of infection, such as fever or sore throat, while taking Aceon?

In very rare instances, the ACE inhibitor class of drugs can be associated with blood or bone marrow disorders. These disorders may present as signs of infection, such as fever or a persistent sore throat. Regulatory-affiliated patient information advises seeking medical attention if such symptoms develop.

Q: Why might a doctor advise temporarily stopping Aceon before a major surgery?

Official warnings note that ACE inhibitors can cause dangerously low blood pressure (symptomatic hypotension), especially when their effects are combined with anesthesia used during major surgery. Temporarily stopping the medication is a common precautionary measure related to this risk.

Q: Can Aceon affect blood sugar levels in people who have diabetes?

Regulatory patient information states that Aceon can potentially lower blood sugar (glucose) levels in people with diabetes. Official guidance includes the recommendation for blood sugar levels to be monitored more frequently, particularly when treatment is initiated.

Q: Does Aceon interact with medicines used to treat high cholesterol?

Official clinical trials indicate that Aceon has been used alongside various other medications. Formal regulatory interaction lists generally do not include specific contraindications for combination use with common lipid-lowering agents (like statins).

Q: Are there specific warnings about sunlight exposure while taking Aceon?

Official adverse reaction reporting includes photosensitivity reactions, or increased sensitivity to sunlight, as an uncommon side effect of Aceon. Caution with sun exposure may be relevant for some users.

Q: Is the brand-name drug Aceon medically different from the generic version, perindopril?

The active substance in both is perindopril. Generic versions are required by regulatory bodies to be bioequivalent to the brand-name drug. This means the generic product must work the same way in the body and deliver the same amount of active ingredient at the same rate.

Q: How does Aceon compare to other medications in terms of the likelihood of causing a dry cough?

The dry cough is a commonly reported side effect associated with the entire class of Angiotensin-Converting Enzyme (ACE) Inhibitors. Official regulatory information states the cough is a very common side effect of perindopril, but the documents generally do not provide direct, formal comparative data on the incidence of cough versus other specific ACE inhibitors.

Q: Are there any reported interactions between Aceon and common cold or flu medications?

Official drug interaction databases note that some cold and flu medications contain ingredients, like sympathomimetic agents (decongestants), which can raise blood pressure. This may potentially counteract the effect of Aceon. Official information indicates that co-administration may require careful consideration.

Q: Can perindopril (Aceon) increase the risk of getting muscle cramps?

Official regulatory adverse event reporting lists muscle cramps as a common side effect of Aceon. Muscle pain, or myalgia, is also noted as an uncommon side effect in some documents.

Q: Is the maximum recommended dosage of Aceon the same for all conditions it treats?

No. Official prescribing information indicates that the maximum recommended daily dosage of Aceon is specific to the condition being managed. For example, the maximum dose for the treatment of hypertension is typically different from the maximum dose for stable coronary artery disease.

Q: Why is close medical monitoring recommended during the first few weeks of starting Aceon?

Close medical monitoring is officially recommended because the risk of experiencing symptomatic hypotension, or dangerously low blood pressure, is highest immediately after the initial dose is taken or when the dose is increased. This monitoring ensures the medication is tolerated safely during the body’s initial adjustment period.

How should Aceon be stored and disposed of?

The storage and disposal of Aceon (perindopril erbumine) tablets must strictly follow official regulatory requirements to maintain product stability and safety.


Storage Requirements

Temperature and Protection: The medicine must be stored at a Controlled Room Temperature of 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and light and should not be frozen.

Handling and Safety: Tablets must be kept in their original, tightly closed package until use. Aceon must always be stored out of the sight and reach of children.


Disposal Instructions

Unused or expired Aceon tablets must be disposed of in accordance with local requirements for pharmaceutical waste. Do not flush the medicine down the toilet or throw it into household trash, as this helps prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aceon found in:

A-Z Index: